EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Impact of SGLT2 Inhibition on Markers of Reverse Cardiac Remodelling in Heart Failure: Systematic Review and Meta-Analysis

Einfluss der SGLT2-Hemmung auf Marker des Reverse Cardiac Remodelling bei Herzinsuffizienz: systematische Übersicht und Metaanalyse

Patrick Savage iD, Chris Watson, Jaimie Coburn, Brian Cox, Michael Shahmohammadi, David Grieve, Lana Dixon

ESC Heart Failure · 01.12.2024 · 11 (6) · 3636-3648

DOI: 10.1002/ehf2.14993 ↗

Auf einen Blick

Sieben randomisierte, placebokontrollierte Studien mit 657 Patient:innen untersuchten SGLT2-Inhibitoren bei Herzinsuffizienz. Mehrere Echokardiographie- und MRT-Marker des Reverse Cardiac Remodelling verbesserten sich gegenüber Placebo.

Fragestellung

Beeinflusst eine SGLT2-Hemmung bei Herzinsuffizienz Marker des Reverse Cardiac Remodelling im Vergleich zu Placebo?

Methode

Systematische Übersicht und Metaanalyse randomisierter, placebokontrollierter Studien; Datenbanken PubMed, EMBASE, MEDLINE und Cochrane Library; random-effects-Modell; Subgruppen nach Bildgebung.

Ergebnisse

7 randomisierte, placebokontrollierte Studien mit 657 Patient:innen. Signifikante Verbesserungen bei LVEDV, LVEDVi, LVESV, LVESVi, LVM, LVMi und LVEF. Kein signifikanter Unterschied bei GLS oder LAVi.

Schlussfolgerung der Autor:innen

Die Metaanalyse liefert zusätzliche Daten zu den Effekten der SGLT2-Hemmung auf Reverse Cardiac Remodelling bei Herzinsuffizienz. Gegenüber Placebo zeigten sich signifikante Verbesserungen mehrerer Marker.

Kernaussagen

  • LVEDV, LVEDVi, LVESV und LVESVi verbesserten sich gegenüber Placebo.
  • Auch LVM, LVMi und LVEF zeigten signifikante Verbesserungen.
  • Kein signifikanter Unterschied bei GLS oder LAVi.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift ESC Heart Failure, online erschienen am 26.07.2024. Verfasst von Patrick Savage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Ventricular Remodeling. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Belfast Heart Trust Fund.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Several landmark randomized-controlled trials (RCTs) have demonstrated the efficacy of sodium-glucose co-transport 2 (SGLT2) inhibitors in reducing all-cause mortality, cardiovascular (CV) mortality and heart failure (HF) hospitalizations. Much interest surrounds their mechanism of action and whether they have direct effects on reverse cardiac remodelling. Therefore, we conducted a meta-analysis of placebo controlled RCTs evaluating the impact of SGLT2 inhibition on imaging derived markers of reverse cardiac remodelling in patients with HF.

Methods

We performed a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement and Cochrane Collaboration. Data interrogation of each major database including PubMed, EMBASE, MEDLINE and Cochrane Library was performed. RCTs evaluating HF patients >18 years comparing SGLT2 inhibitor versus placebo-control were included. Outcome measures included left ventricular end-diastolic volume and volume index (LVEDV/LVEDVi), left ventricular end-systolic volume and volume index (LVSDV/LVSDVi), left ventricular ejection fraction (LVEF), left ventricular mass index (LVMi), left atrial volume index (LAVi) and left ventricular global longitudinal strain (LV GLS). Studies with an HF with preserved ejection fraction population were excluded from analysis of parameters, which would be significantly affected by baseline LVEF, such as volumes and LVEF. The mean difference and standard error were extracted from each study and a random effects model used pool the mean difference and standard error across studies. A pre-specified sub-group analysis was performed to stratify results according to imaging modality used (cardiac magnetic resonance imaging and echocardiography). This study is registered on PROSPERO: CRD42023482722.

Results

Seven randomized, placebo-controlled trials in patients with HF comprising a total population of 657 patients were included. Overall LVEF of included studies ranged from 29 ± 8.0% to 55.5 ± 4.2%. In studies included in analysis of HFrEF parameters, baseline LVEF ranged from 29 ± 8% to 45.5 ± 12%. Pooled data demonstrated SGLT2 inhibition, compared with placebo control, resulted in significant improvements in mean difference of LVEDV [−11.62 ml (95% confidence interval, CI −17.90 to −5.25; z = 3.67, P = 0.0004)], LVEDVi [−6.08 ml (95% CI −9.96 to −2.20; z = 3.07; P = 0.002)], LVESV [−12.47 ml (95% CI −19.12 to −5.82; z = 3.68; P = 0.0002)], LVESVi [−6.02 ml (95% CI −10.34 to −1.70; z = 2.73; P = 0.006)], LVM [−9.77 g (95% CI −17.65 to −1.89; z = 2.43; P = 0.02)], LVMi (−3.52 g [95% CI −7.04 to 0.01; z = 1.96; P = 0.05)] and LVEF [+2.54 mL (95% CI 1.10 to 3.98; z = 3.62; P = 0.0005)]. No significant difference in GLS (n = 327) [+0.42% (95%CI −0.19 to 1.02; P = 0.18)] or LAVi [−3.25 ml (95% CI −8.20 to 1.69; z = 1.29; P = 0.20)] was noted.

Conclusion

This meta-analysis provides additional data and insight into the effects of SGLT2 inhibition on reverse cardiac remodelling in patients with HF. Compared with placebo control, we found that treatment with a SGLT2 inhibitor produced significant improvements in several markers of reverse cardiac remodelling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsHeart FailureVentricular RemodelingHumansVentricular Function, LeftStroke Volume

Stichwörter der Autor:innen

SGLT2 inhibitorsbiomarkerscardiac imagingheart failureremodelling

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
  • Royal Victoria Hospital, Belfast, UK.

ORCID-Profile: Patrick Savage

Förderung

  • British Heart Foundation
  • Belfast Heart Trust Fund

Zitieren

APA

Savage, P., Watson, C., Coburn, J., Cox, B., Shahmohammadi, M., Grieve, D., & Dixon, L. (2024). Impact of SGLT2 Inhibition on Markers of Reverse Cardiac Remodelling in Heart Failure: Systematic Review and Meta-Analysis. ESC Heart Failure, 11(6), 3636-3648. https://doi.org/10.1002/ehf2.14993

Vancouver

Savage P, Watson C, Coburn J, Cox B, Shahmohammadi M, Grieve D, et al. Impact of SGLT2 Inhibition on Markers of Reverse Cardiac Remodelling in Heart Failure: Systematic Review and Meta-Analysis. ESC Heart Failure. 2024;11(6):3636-3648. doi:10.1002/ehf2.14993

BibTeX
@article{Savage2024,
  author = {Savage, Patrick and Watson, Chris and Coburn, Jaimie and Cox, Brian and Shahmohammadi, Michael and Grieve, David and Dixon, Lana},
  title = {Impact of SGLT2 Inhibition on Markers of Reverse Cardiac Remodelling in Heart Failure: Systematic Review and Meta-Analysis},
  journal = {ESC Heart Failure},
  year = {2024},
  volume = {11},
  number = {6},
  pages = {3636--3648},
  doi = {10.1002/ehf2.14993}
}
Kostenlos starten →